212 related articles for article (PubMed ID: 37999621)
21. A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C.
El-Kassas M; Emadeldeen M; Hassany M; Esmat G; Gomaa AA; El-Raey F; Congly SE; Liu H; Lee SS
J Hepatol; 2023 Aug; 79(2):314-320. PubMed ID: 37088312
[TBL] [Abstract][Full Text] [Related]
22. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
[TBL] [Abstract][Full Text] [Related]
23. No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Sarrazin C; Cooper CL; Manns MP; Reddy KR; Kowdley KV; Roberts SK; Dvory-Sobol H; Svarovskia E; Martin R; Camus G; Doehle BP; Stamm LM; Hyland RH; Brainard DM; Mo H; Gordon SC; Bourliere M; Zeuzem S; Flamm SL
J Hepatol; 2018 Dec; 69(6):1221-1230. PubMed ID: 30098373
[TBL] [Abstract][Full Text] [Related]
24. Treatment Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir in Direct-Acting Antiviral-Experienced Hepatitis C Virus Patients: A Systematic Review and Meta-Analysis.
Devan P; Tiong KLA; Neo JE; Mohan BP; Wijarnpreecha K; Tam YCS; Coppola N; Preda CM; Wong YJ
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515176
[TBL] [Abstract][Full Text] [Related]
25. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C.
Majethia S; Lee IH; Chastek B; Bunner S; Wolf J; Hsiao A; Mozaffari E
J Manag Care Spec Pharm; 2022 Jan; 28(1):48-57. PubMed ID: 34677088
[No Abstract] [Full Text] [Related]
26. Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.
Parigi TL; Torres MCP; Aghemo A
Clin Mol Hepatol; 2019 Dec; 25(4):360-365. PubMed ID: 31042864
[TBL] [Abstract][Full Text] [Related]
27. Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study.
Mangia A; Scaglione F; Toniutto P; Pirisi M; Coppola N; Di Perri G; Alvarez Nieto G; Calabrese S; Hernandez C; Perrone V; Degli Esposti L; Fagiuoli S
Int J Environ Res Public Health; 2021 Jul; 18(13):. PubMed ID: 34281080
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Da BL; Lourdusamy V; Kushner T; Dieterich D; Saberi B
Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):859-861. PubMed ID: 32541241
[TBL] [Abstract][Full Text] [Related]
29. Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy.
Smith DA; Bradshaw D; Mbisa JL; Manso CF; Bibby DF; Singer JB; Thomson EC; da Silva Filipe A; Aranday-Cortes E; Ansari MA; Brown A; Hudson E; Benselin J; Healy B; Troke P; McLauchlan J; Barnes E; Irving WL
J Viral Hepat; 2021 Sep; 28(9):1256-1264. PubMed ID: 34003556
[TBL] [Abstract][Full Text] [Related]
30. Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis.
Shahid S; Asghar S; Mahmood T; Fatima M; Rasheed A; Asghar S
Cureus; 2023 Sep; 15(9):e45680. PubMed ID: 37868481
[TBL] [Abstract][Full Text] [Related]
31. The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis.
Chen R; Xiong Y; Zeng Y; Wang X; Xiao Y; Zheng Y
Front Public Health; 2023; 11():1179531. PubMed ID: 37841743
[TBL] [Abstract][Full Text] [Related]
32. Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
Younossi ZM; Stepanova M; Jacobson IM; Asselah T; Gane EJ; Lawitz E; Foster GR; Roberts SK; Thompson AJ; Willems BE; Welzel TM; Pearlman B; Younossi I; Racila A; Henry L
Aliment Pharmacol Ther; 2018 Jan; 47(2):259-267. PubMed ID: 29181842
[TBL] [Abstract][Full Text] [Related]
33. Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.
Liu CH; Kao JH
Hepatol Int; 2022 Oct; 16(5):1001-1019. PubMed ID: 35876967
[TBL] [Abstract][Full Text] [Related]
34. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Soria A; Fava M; Bernasconi DP; Lapadula G; Colella E; Valsecchi MG; Migliorino GM; D'Ambrosio R; Landonio S; Schiavini M; Spinetti A; Carriero C; Degasperi E; Cologni G; Gatti F; Viganò P; Hasson H; Uberti-Foppa C; Pasulo L; Baiguera C; Rossotti R; Vinci M; Puoti M; Giorgini A; Menzaghi B; Lombardi A; Pan A; Aghemo A; Grossi PA; Boldizzoni R; Colombo S; Viganò M; Rumi MG; Del Poggio P; Valenti L; Giglio O; De Bona A; d'Arminio Monforte A; Colombo A; Spinelli O; Pigozzi MG; Molteni C; Bonfanti P; Terreni N; Perini P; Capretti A; Bella D; Liani C; Polo S; Aimo G; Pagnucco L; Bhoori S; Centenaro R; Graffeo M; Ciaccio A; Dionigi E; Lazzaroni S; Carderi I; Di Marco M; Rizzardini G; Noventa F; Lampertico P; Fagiuoli S
Liver Int; 2020 Apr; 40(4):769-777. PubMed ID: 31970845
[TBL] [Abstract][Full Text] [Related]
35. Concomitant use of direct-acting antivirals (DAA) and central nervous system drugs in patients with hepatitis C virus infection.
Sicras-Mainar A; Morillo-Verdugo R
Adicciones; 2022 Nov; 34(4):279-284. PubMed ID: 33338248
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness of Direct-Acting Antivirals for Posttraumatic Stress Disorder in Veterans Affairs Patients With Hepatitis C Virus Infection.
Shiner B; Huybrechts K; Gui J; Rozema L; Forehand J; Watts BV; Jiang T; Hoyt JE; Esteves J; Schnurr PP; Ray K; Gradus JL
Am J Epidemiol; 2022 Aug; 191(9):1614-1625. PubMed ID: 35689641
[TBL] [Abstract][Full Text] [Related]
38. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
[TBL] [Abstract][Full Text] [Related]
39. Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
Liu CH; Su TH; Liu CJ; Chen PJ; Chen DS; Kao JH
J Formos Med Assoc; 2020 Dec; 119(12):1871-1875. PubMed ID: 32553687
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain.
Sicras Mainar A; Navarro Artieda R; Hernández I; Morillo R
Gastroenterol Hepatol; 2019 Oct; 42(8):465-475. PubMed ID: 31451229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
